Is This the Right Reference Standard Diagnosis for Retinopathy of Prematurity? - Reply

TY - JOUR

T1 - Is This the Right Reference Standard Diagnosis for Retinopathy of Prematurity? - Reply

AU - Redd, Travis K.

AU - Campbell, J. Peter

AU - Chiang, Michael

N1 - Funding Information: Dr Bernstein reports grants from Foundation Fighting Blindness during the conduct of the study; personal fees from Spark Therapeutics, Acucela, Makindus, and ScienceBased Health outside the submitted work; and grants from the National Institutes of Health outside the submitted work. Funding Information: Dr Lam reports grants from the National Eye Institute and Foundation Fighting Blindness during the conduct of the study; grants from Applied Genetic Technologies Corporation, Night-star, Astellas Pharmaceuticals, Quark Pharmaceuticals, Second Sight, Sanofi, and Editas Medicine outside the submitted work; and personal fees from Spark Therapeutics, Shire, and Ionis Pharmaceuticals outside the submitted work. Funding Information: Conflict of Interest Disclosures: All authors have completed and submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Dr Chiang reports serving as an unpaid member of the scientific advisory board for Clarity Medical Systems, a consultant for Novartis, and an initial member of Inteleretina, LLC; in addition, he received grants from the National Institutes of Health (R01 EY19474 and P30 EY010572) and the National Science Foundation (SCH-1622679, SCH-1622542, and SCH-1622536) and unrestricted departmental funding from Research to Prevent Blindness to support the original investigation to which this letter refers. No other disclosures were reported. Funding Information: Dr Hartnett reports grants from the National Eye Institute and Foundation Fighting Blindness during the conduct of the study; personal fees from SanBio outside the submitted work; and has a patent U-5618 pending. Funding Information: Dr Iannaccone reports grants from Foundation Fighting Blindness Clinical Research Institute during the conduct of the study; grants from BCM Families Foundation and Foundation Fighting Blindness Clinical Research Institute outside the submitted work; personal fees from Ionis Pharmaceuticals, Advance Medical, EyeCRO, ClearView Healthcare Partners, Ger-son Lehrman Group, and Huron Consulting Group outside the submitted work; and other support from Applied Genetic Technologies Corporation, Shire Human Genetic Therapies, and Allergan/RetroSense outside the submitted work.

PY - 2018/12

Y1 - 2018/12

UR - http://www.scopus.com/inward/record.url?scp=85053805167&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85053805167&partnerID=8YFLogxK

U2 - 10.1001/jamaophthalmol.2018.4181

DO - 10.1001/jamaophthalmol.2018.4181

M3 - Letter

C2 - 30326039

AN - SCOPUS:85053805167

SN - 2168-6165

VL - 136

SP - 1429

EP - 1430

JO - JAMA Ophthalmology

JF - JAMA Ophthalmology

IS - 12

ER -